Economic TimesGlaxoSmithKline’s blockbuster dreams dashed as darapladib goes 0-for-2 in PhIIIFierceBiotechGlaxoSmithKline’s last-minute gambit to switch the primary endpoint in its remaining Phase III study of the heart drug darapladib failed to pay off. The pharma giant says that its top cardio prospect flunked the second big trial just as it had the first, leaving the …GSK share price: Heart drug fails late-stage trialiNVEZZGSK heart drug fails late-stage trialDelhi Daily NewsGSK says heart drug darapladib fails in second late-stage trialReutersWall Street Journal -IFA Magazineall 18 news articles …Read Full Story
GlaxoSmithKline's blockbuster dreams dashed as darapladib goes 0-for-2 in PhIII - FierceBiotech
Real Estate of Cebu
